Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 May 24

PMID 34025664

Citations 29

Authors

Dan Liu

Xue Yang

Xiongzhi Wu

Affiliations

Soon will be listed here.

Abstract

Background: The tumor microenvironment (TME) involves infiltration of multiple immune cell subsets, which could influence the prognosis and clinical characteristics. The increasing evidence on the role of tumor-infiltrating lymphocytes (TILs) in primary and metastatic melanomas supports that the immune system is involved in the progression and outcomes of melanoma. However, the immune infiltration landscape in melanoma has not been systematically elucidated.

Methods: In this study, we used CIBERSORT and ESTIMATE algorithms to analyze immune infiltration pattern of 993 melanoma samples. Then we screened differential expression genes (DEGs) related to immune subtypes and survival. The immune cell infiltration (ICI) score was constructed by using principal-component analysis (PCA) based on immune signature genes from DGEs. Gene set enrichment analysis (GSEA) was applied to explore high and low ICI score related pathways. Finally, the predictive ability of ICI score was evaluated in survival prognosis and immunotherapy benefit.

Result: We identified three ICI clusters and three gene clusters associated with different immune subtypes and survival outcomes. Then the ICI score was constructed, and we found that high ICI score exhibited activated immune characteristics and better prognosis. High ICI score was significantly enriched in immune pathways and highly expressed immune signature genes. More importantly, we confirmed that melanoma patients with high ICI score had longer overall survival and rate of response to immunotherapy.

Conclusion: We presented a comprehensive immune infiltration landscape in melanoma. Our results will facilitate understanding of the melanoma tumor microenvironment and provide a new immune therapy strategy.

Citing Articles

Characterization of the immune cell infiltration patterns in lung adenocarcinoma to facilitate immunotherapy.

Li H, Qin Z, Huang X, Wei Z, Deng J Heliyon. 2025; 11(4):e42720.

PMID: 40066042 PMC: 11891687. DOI: 10.1016/j.heliyon.2025.e42720.

CDKN2A, a key gene in copper-induced cell death model, influencing melanoma invasion and apoptosis.

Li J, Yang X, Yin C, Li S, Xu Y, Liu B Discov Oncol. 2025; 16(1):246.

PMID: 40014167 PMC: 11867994. DOI: 10.1007/s12672-025-01992-8.

DSCC1 Identified as Promising Tumor Biomarker and Potential Therapeutic Target Through Comprehensive Multi-omics Analysis and Experimental Validation.

Cheng W, Lin P Mol Biotechnol. 2025; .

PMID: 39992486 DOI: 10.1007/s12033-025-01404-w.

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers.

Strati A, Adamopoulos C, Kotsantis I, Psyrri A, Lianidou E, Papavassiliou A Int J Mol Sci. 2025; 26(3).

PMID: 39941003 PMC: 11818137. DOI: 10.3390/ijms26031235.

Identification of PIF1 as a Ferroptosis-Related Prognostic Biomarker Correlated with Immune Infiltration in Hepatocellular Carcinoma.

Liu F, Yin P, Lu L, Yao J, Jiao B Appl Biochem Biotechnol. 2025; .

PMID: 39888492 DOI: 10.1007/s12010-024-05161-5.

References

Shklovskaya E, Lee J, Lim S, Stewart A, Pedersen B, Ferguson P . Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. Cancers (Basel). 2020; 12(11). PMC: 7696726. DOI: 10.3390/cancers12113374. View

Lee N, Zakka L, Mihm Jr M, Schatton T . Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016; 48(2):177-87. DOI: 10.1016/j.pathol.2015.12.006. View

Cohen C, Gartner J, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky V . Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 2015; 125(10):3981-91. PMC: 4607110. DOI: 10.1172/JCI82416. View

Fukumoto T, Lin J, Fatkhutdinov N, Liu P, Somasundaram R, Herlyn M . ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. J Invest Dermatol. 2020; 141(6):1564-1572.e4. DOI: 10.1016/j.jid.2020.11.026. View

Gide T, Wilmott J, Scolyer R, Long G . Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clin Cancer Res. 2017; 24(6):1260-1270. DOI: 10.1158/1078-0432.CCR-17-2267. View

Yarchoan M, Albacker L, Hopkins A, Montesion M, Murugesan K, Vithayathil T . PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019; 4(6). PMC: 6482991. DOI: 10.1172/jci.insight.126908. View

Kato J, Uhara H . Immunotherapy for advanced melanoma: current situation in Japan. Jpn J Clin Oncol. 2020; 51(1):3-9. DOI: 10.1093/jjco/hyaa188. View

Gajewski T, Woo S, Zha Y, Spaapen R, Zheng Y, Corrales L . Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013; 25(2):268-76. DOI: 10.1016/j.coi.2013.02.009. View

Pozniak J, Nsengimana J, Laye J, OShea S, Diaz J, Droop A . Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. Cancer Res. 2019; 79(10):2684-2696. PMC: 6544535. DOI: 10.1158/0008-5472.CAN-18-2864. View

10.

Chan T, Yarchoan M, Jaffee E, Swanton C, Quezada S, Stenzinger A . Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2018; 30(1):44-56. PMC: 6336005. DOI: 10.1093/annonc/mdy495. View

11.

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

12.

de Azevedo R, Shoshan E, Whang S, Markel G, Jaiswal A, Liu A . MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. Oncoimmunology. 2020; 9(1):1846915. PMC: 7733907. DOI: 10.1080/2162402X.2020.1846915. View

13.

Zeng Y, Zeng Y, Yin H, Chen F, Wang Q, Yu X . Exploration of the immune cell infiltration-related gene signature in the prognosis of melanoma. Aging (Albany NY). 2021; 13(3):3459-3482. PMC: 7906183. DOI: 10.18632/aging.202279. View

14.

Zhang X, Shi M, Chen T, Zhang B . Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. Mol Ther Nucleic Acids. 2020; 22:298-309. PMC: 7522342. DOI: 10.1016/j.omtn.2020.08.030. View

15.

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J . Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98(4):262-72. DOI: 10.1093/jnci/djj052. View

16.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

17.

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

18.

Tacastacas J, Bray J, Cohen Y, Arbesman J, Kim J, Koon H . Update on primary mucosal melanoma. J Am Acad Dermatol. 2014; 71(2):366-75. DOI: 10.1016/j.jaad.2014.03.031. View

19.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

20.

Marzagalli M, Ebelt N, Manuel E . Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol. 2019; 59:236-250. DOI: 10.1016/j.semcancer.2019.08.002. View